TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06484920: A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL

Sponsor: Rita Assi · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 24 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$5,913,600

Rescue Site Savings

+$3,880,800

Unlock Full NCT06484920 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06484920 Rescue Dossier →